OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
Key Highlights
- ➤OKYO Pharma (OKYO) to present at Eyecelerator on October 8, 2026
- ➤CEO Robert J. Dempsey presenting on corneal and anterior segment diseases
- ➤Leadership team attending optometry and ophthalmology conferences September 30-October 12
- ➤Global Phase 3 trial planned for second half, enrolling approximately 111 NCP patients
* OKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.
Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases Presentation Date/Time: Thursday, October 8, 2026, 1:29 PM CT Breakout: Anterior Segment, Room 243-245 Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO Pharma Moderators: Julie Schallhorn, MD, MS; Kendall Donaldson, MD
Get started
Create a free account to read the full story.